Acumen Pharmaceuticals Inc's Customers Performance

Name: Acumen Pharmaceuticals Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

ABOS

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


ABOS's Source of Revenues		• List of ABOS Customers

for the same period Acumen Pharmaceuticals Inc

• List of ABOS Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Acumen Pharmaceuticals Inc's Comment on Sales, Marketing and Customers

News about Acumen Pharmaceuticals Inc Contracts

Acumen Pharmaceuticals Expands Partnership with Lonza A Step Forward in Alzheimers Treatment Amid Market Challenges

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a biopharmaceutical company at the forefront of Alzheimer s disease (AD) treatment, recently announced an extension of its collaboration with Lonza, a leading global manufacturing partner. This strategic partnership aims to enhance the development and potential commercialization of sabirnetug (ACU193), a novel therapeutic agent designed to target toxic soluble amyloid beta (A) oligomers, a key contributor to the pathophysiology of Alzheimer s disease. While this collaboration signifies a crucial step in the fight against Alzheimer’s, Acumen s stock performance has raised some concerns, as it has trailed behind broader market trends throughout the month. Acumen s...

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheime...

Unveiling New Insights: Acumen Pharmaceuticals Showcases Promising Data from the INTERCEPT-AD Study at AAIC 2024In a significant stride towards advancing Alzheimer s disease (AD) research and treatment, Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) recently presented pivotal findings from its Phase 1 INTERCEPT-AD study during the Alzheimer s Association International Conference (AAIC) 2024. The conference, held in Philadelphia and online from July 28 to August 1, gathered leading experts and researchers from around the globe to discuss the latest developments in Alzheimer’s research.Acumen Pharmaceuticals, a clinical-stage biopharmaceutical entity dedicated to pioneering therapeutics targeting toxic soluble...

ABOS's Stock Performance relative to it's Customers

ABOS's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Acumen Pharmaceuticals Inc	205.91	0.00	-113.28	61
SUBTOTAL	0.00	0.00	0.00	-

Sources: Acumen Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Acumen Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Acumen Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.